A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression.
Hepatocellular carcinoma
Liver
Malignancy
Progressive disease
Ramucirumab
Response
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
24
01
2020
accepted:
28
01
2020
entrez:
2
5
2020
pubmed:
2
5
2020
medline:
2
5
2020
Statut:
epublish
Résumé
A 73-year-old male was initially treated with sorafenib for advanced stage HCC. However, the disease progressed 2 months after starting sorafenib. Progressive disease (PD) was confirmed by radiological examination, which revealed mediastinal and abdominal lymph node metastasis, pulmonary metastasis, and intrahepatic recurrence. The patient was enrolled in the REACH-2 (NCT02435433) trial and randomized to receive ramucirumab (8 mg/kg div. every 2 weeks). The patient had a Child-Pugh score of 6A and his AFP level was found to be 1,256.8 ng/mL at initiation. Radiological examination revealed PD, 5 months after starting ramucirumab. Ramucirumab treatment was continued after the confirmation of radiological PD, not but clinical progression, as allowed by the study protocol. His AFP level increased after continuous ramucirumab treatment, however, it suddenly decreased from 7,653 ng/mL to within normal limits 10 months after initiation of ramucirumab treatment. Radiological evaluation revealed a significant decrease in the size of the tumors, which constituted a partial response (PR). We reported a rare case of advanced HCC with PR to a continuous ramucirumab treatment after radiological PD.
Identifiants
pubmed: 32355493
doi: 10.1159/000506331
pii: cro-0013-0379
pmc: PMC7184828
doi:
Types de publication
Case Reports
Langues
eng
Pagination
379-384Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Oncotarget. 2016 Mar 22;7(12):15243-51
pubmed: 26893366
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Br J Cancer. 2019 Aug;121(4):340-343
pubmed: 31285588
Hepatol Res. 2014 Mar;44(3):296-301
pubmed: 23607549
Aliment Pharmacol Ther. 2017 Apr;45(8):1146-1155
pubmed: 28252185
PLoS One. 2016 Jan 08;11(1):e0146456
pubmed: 26745625
World J Gastroenterol. 2014 Sep 21;20(35):12581-7
pubmed: 25253961
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759